Synopsys, SNPS and Tech
State Medicaid agencies can improve D-SNP financial transparency and reward those D-SNPs that provide the best value to ...
Dual eligibles — that is, people eligible for both Medicare and Medicaid — have a wealth of Medicare options. These ...
Synopsys SNPS shares plunged 20.8% over the past year, underperforming the Zacks Computer - Software industry, Zacks Computer ...
Synopsys (NASDAQ:SNPS – Free Report) had its price target decreased by Piper Sandler from $655.00 to $653.00 in a report released on Thursday,Benzinga reports. Piper Sandler currently has an ...
This post was written by Luke Carberry Mogan. SNPS' first-quarter performance is likely to have benefited from the rising adoption of EDA, IP solutions and Synopsys.ai platform. Get a deeper ...
Synopsys Inc (NASDAQ:SNPS) shares are trading higher premarket reported first-quarter financial results after the market ...
Synopsys (NASDAQ:SNPS – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a note issued to investors on Thursday,Benzinga reports. They currently have a ...
Despite a dip in overall revenue, Synopsys Inc (SNPS) sees growth in Design Automation and advances in AI-driven solutions.
Loop Capital Markets analyst Gary Mobley reiterated a Buy rating on Synopsys (SNPS – Research Report) today and set a price target of $650.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback